LncRNA SNHG5 promotes nasopharyngeal carcinoma progression by regulating miR-1179/HMGB3 axis

Liu, Dengtao; Wang, Yanpeng; Zhao, Yaqi; Gu, Xiaoqing

doi:10.1186/s12885-020-6662-5

Cited by 41 publications

(27 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SNHG4 is not described for HNSCC, but in lung cancers it affects proliferation, migration and invasiveness, as well as EMT through miR-98-5p [ 52 ]. Similarly, SNHG5 in nasopharyngeal carcinoma regulates the expression of both the miR-1179/HMGB3 axis and cancer progression [ 53 ]. Finally, SNHG6 was indicated in the meta-analysis as an oncogene connected with cancer progression and could be used as a promising prognostic biomarker [ 54 ].…”

Section: Discussionmentioning

confidence: 99%

Liquid lncRNA Biopsy for the Evaluation of Locally Advanced and Metastatic Squamous Cell Carcinomas of the Head and Neck

Łasińska

Kolenda

Guglas

et al. 2020

JPM

View full text Add to dashboard Cite

Background: Long non-coding RNA (lncRNA) are RNA molecules that are more than 200 nucleotides long and have the ability to modify the activity of genes. They can be found in both healthy and cancer tissues, as well as in plasma, saliva and other bodily fluids. They can also be used as biomarkers of early detection, prognosis and chemotherapy resistance in several cancer types. Treatment of head and neck squamous cell carcinoma (HNSCC) patients with locally advanced disease is still difficult, and choice of treatment should be based on more precise and available biomarkers, such as those obtained from a liquid biopsy. For improvement of treatment efficacy, identification and clinical implementation of new biomarkers are of the utmost importance. Methods: Plasma samples drawn before (p1) and three cycles post (p2) (TPF: docetaxel, cisplatin, 5-fluorouracil/PF: cisplatin, 5-fluorouracil) chemotherapy from 53 HNSCC patients (17 with locally advanced and 36 with metastatic disease) and 14 healthy volunteers were studied. Expression levels of 90 lncRNA expression were analyzed using the qRT-PCR method, and the obtained results were compared between proper groups. Statistical analyses were carried out using Jupyter Notebooks (5.7.2), Python (ver. 3.6) and GraphPad Prism 8. Results: The study demonstrated the differences between the expressions of several lncRNA in cancer patients’ and healthy volunteers’ plasma, as well as between locally advanced and metastatic patients’ groups. A correlation between the response to systemic therapy and lncRNA expression levels was observed. Patients with a (high/low) expression of Alpha 250 and Emx2os showed statistically significant differences in progression free survival (PFS), as well as for overall survival (OS) depending on the level of Alpha 250, snaR, SNHG1. The univariate and multivariate Cox regression model showed Alpha 250 as the best prognostic factor for HNSCC patients. Conclusions: Liquid biopsies based on lncRNAs are promising diagnostic tools that can be used to differentiate between those with cancer and healthy individuals. Additionally, they can also serve as biomarkers for chemotherapy resistance. An identified, circulating lncRNA Alpha 250 seems to prove the best prognostic biomarker, associated with extended PFS and OS, and should be validated in a larger cohort in the future.

show abstract

Section: Discussionmentioning

confidence: 99%

Liquid lncRNA Biopsy for the Evaluation of Locally Advanced and Metastatic Squamous Cell Carcinomas of the Head and Neck

Łasińska

Kolenda

Guglas

et al. 2020

JPM

View full text Add to dashboard Cite

show abstract

“…The gene detection performed by Liu et.al 18 in 64 NPC tissues and two NPC cell lines (NP69 and C666-1) indicated that the expression level of SNHG5 was remarkably increased in NPC tissues and cell lines (p < 0.05). Clinically, the relative higher expression of SNHG5 was tightly associated with advanced tumor stage and shorter overall survival.…”

Section: Nasopharyngeal Carcinoma (Npc)mentioning

confidence: 99%

“…9 In nasopharyngeal carcinoma, SNHG5 promoted tumor progression by regulating miR-1179/HMGB3 axis. 18 Moreover, SNHG5 targeted miR-154-5p to weaken the suppressive effect of miR-154-5p on PCNA, which was significantly involved in proliferation of breast cancer cells. 19 Furthermore, miR-26a-5p, which markedly suppressed GSK3β, was inversely correlated with SNHG5 in hepatocellular carcinoma.…”

Section: Biological Mechanisms Of Lncrna Snhg5 In Human Cancers Intermentioning

confidence: 99%

“…17 Additional clinical features analysis revealed that SNHG5 had a close correlation with tumor stage and overall survival. 18 Further functional experiments unfolded that SNHG5 could act as a sponge for miR-154-5p to elevate expression level of proliferating cell nuclear antigen (PCNA), thus markedly promoting proliferation. 19 In addition, Wnt/β-catenin signaling, p38/MAPK signaling, mTOR signaling and ROCK signaling were significantly activated by SNHG5.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

<p>Latest Advances of Long Non-Coding RNA SNHG5 in Human Cancers</p>

Han¹,

Shi²,

Cao³

et al. 2020

OTT

View full text Add to dashboard Cite

Long non-coding RNAs (lncRNAs) have been potent regulators in the initiation and development of human cancers regarding their biological roles in the modulation of dosage compensation effect, epigenetics and cell differentiation. Recently, aberrant expression of lncRNA small nucleolar RNA host gene 5 (SNHG5) has been observed in various solid tumors, which was intently correlated with tumor range, metastasis, pathological stage and prognosis. Additional mechanical investigation disclosed that SNHG5 was involved in multiple cellular activities, including proliferation, migration, invasion, cell-cycle, apoptosis and autophagy, via targeting miRNAs, signaling pathways and other biological molecules or proteins. In this review, we summarized the latest advances made towards understanding the roles of SNHG5 in human cancers and further discussed potential methods that could be adopted for clinical interventions.

show abstract

“…have been associated with many types of cancers including breast cancer, hepatocellular carcinoma, colorectal cancer, prostate cancer, acute promyelocytic leukemia, among others (reviewed in [52] and [53]), however, there is much quiescence regarding their role in NPC. Furthermore, only a few recent studies have demonstrated the upregulation of lncRNA small nucleolar RNA host genes (SNHGs) such as SNHG5 [54], SNHG7 [55,56], SNHG12 [57] and SNHG20 [58] in the blood and tissue samples of NPC patients. Thus, we focused on miRNA and long noncoding RNA for which there is more evidence to support the prognostic and diagnostic potentials in NPC, particularly using human subjects.…”

Section: Noncoding Rnas In Npcmentioning

confidence: 99%

Diagnostic and Prognostic Indications of Nasopharyngeal Carcinoma

Irekeola

Yean

2020

Diagnostics

View full text Add to dashboard Cite

Nasopharyngeal carcinoma (NPC) is a disease that is highly associated with the latent infection of Epstein–Barr virus. The absence of obvious clinical signs at the early stage of the disease has made early diagnosis practically impossible, thereby promoting the establishment and progression of the disease. To enhance the stride for a reliable and less invasive tool for the diagnosis and prognosis of NPC, we synopsize biomarkers belonging to the two most implicated biological domains (oncogenes and tumor suppressors) in NPC disease. Since no single biomarker is sufficient for diagnosis and prognosis, coupled with the fact that the known established methods such as methylation-specific polymerase chain reaction (PCR), multiplex methylation-specific PCR, microarray assays, etc., can only accommodate a few biomarkers, we propose a 10-biomarker panel (KIT, LMP1, PIKC3A, miR-141, and miR-18a/b (oncogenic) and p16, RASSF1A, DAP-kinase, miR-9, and miR-26a (tumor suppressors)) based on their diagnostic and prognostic values. This marker set could be explored in a multilevel or single unified assay for the diagnosis and prognosis of NPC. If carefully harnessed and standardized, it is hoped that the proposed marker set would help transform the diagnostic and prognostic realm of NPC, and ultimately, help prevent the life-threatening late-stage NPC disease.

show abstract

LncRNA SNHG5 promotes nasopharyngeal carcinoma progression by regulating miR-1179/HMGB3 axis

Cited by 41 publications

References 21 publications

Liquid lncRNA Biopsy for the Evaluation of Locally Advanced and Metastatic Squamous Cell Carcinomas of the Head and Neck

Liquid lncRNA Biopsy for the Evaluation of Locally Advanced and Metastatic Squamous Cell Carcinomas of the Head and Neck

<p>Latest Advances of Long Non-Coding RNA SNHG5 in Human Cancers</p>

Diagnostic and Prognostic Indications of Nasopharyngeal Carcinoma

Contact Info

Product

Resources

About